Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

التفاصيل البيبلوغرافية
العنوان: Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
المؤلفون: Aurélie Maran-Gonzalez, Jean Pierre Ghnassia, Magali Lacroix-Triki, Eva Brabencova, Delphine Loussouarn, Juliette Haudebourg, Thomas Filleron, Sarah Lefèvre, Frédérique Penault-Llorca, C. Courtinard, Suzette Delaloge, Emmanuelle Charafe-Jauffret, Véronique Verriele, Thomas Grinda, Natacha Joyon, Camille Franchet, Isabelle Treilleux, Amélie Lusque, Patrick Tas, Jean-Yves Scoazec, Cécile Blanc-Fournier, Gaëtan MacGrogan, Anca Berghian, Agnès Leroux, Anne Vincent-Salomon, Laurent Arnould, Etienne Brain
المساهمون: Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER
المصدر: npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
npj Breast Cancer
npj Breast Cancer, Nature, 2021, 7 (1), ⟨10.1038/s41523-021-00252-6⟩
NPJ Breast Cancer
بيانات النشر: Springer Science and Business Media LLC, 2021.
سنة النشر: 2021
مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, [SDV]Life Sciences [q-bio], medicine.medical_treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease, Predictive markers, Article, Metastasis, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Internal medicine, Biopsy, medicine, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, skin and connective tissue diseases, RC254-282, medicine.diagnostic_test, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Metastatic breast cancer, 3. Good health, 030104 developmental biology, Hormone receptor, 030220 oncology & carcinogenesis, Cohort, business, Adjuvant
الوصف: Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME database, a National real-life multicenter cohort of MBC patients. Patients with results available on both primary tumour and metastatic disease within 6 months of MBC diagnosis and before any tumour progression were eligible for the main analysis. Among the 16,703 patients included in the database, 1677 (10.0%) had available biopsy results at MBC diagnosis and on matched primary tumour. The change rate of either HR or HER2 was 27.0%. Global HR status changed (from positive = either ER or PR positive, to negative = both negative; and reverse) in 14.2% of the cases (expression loss in 72.5% and gain in 27.5%). HER2 status changed in 7.8% (amplification loss in 45.2%). The discordance rate appeared similar across different biopsy sites. Metastasis to bone, HER2+ and RH+/HER2- subtypes and previous adjuvant endocrine therapy, but not relapse interval were associated with an HR discordance in multivariable analysis. Loss of HR status was significantly associated with a risk of death (HR adjusted = 1.51, p = 0.002) while gain of HR and HER2 discordance was not. In conclusion, discordance of HR and HER2 expression between primary and metastatic breast cancer cannot be neglected. In addition, HR loss is associated with worse survival. Sampling metastatic sites is essential for treatment adjustment.
تدمد: 2374-4677
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba74d9e680adfb3b37c5f19837953234
https://doi.org/10.1038/s41523-021-00252-6
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....ba74d9e680adfb3b37c5f19837953234
قاعدة البيانات: OpenAIRE